Loading…

Surgical management, DNA content, and patient survival in adrenal cortical carcinoma

Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgi...

Full description

Saved in:
Bibliographic Details
Published in:Surgery 1995-12, Vol.118 (6), p.1090-1098
Main Authors: Lee, Jeffrey E., Berger, David H., El-Naggar, Adel K., Hickey, Robert C., Vassilopoulou-Sellin, Rena, Gagel, Robert F., Andrew Burgess, M., Evans, Douglas B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3
cites cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3
container_end_page 1098
container_issue 6
container_start_page 1090
container_title Surgery
container_volume 118
creator Lee, Jeffrey E.
Berger, David H.
El-Naggar, Adel K.
Hickey, Robert C.
Vassilopoulou-Sellin, Rena
Gagel, Robert F.
Andrew Burgess, M.
Evans, Douglas B.
description Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients. Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid). Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.
doi_str_mv 10.1016/S0039-6060(05)80119-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77714969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0039606005801199</els_id><sourcerecordid>77714969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRaq3-hEJOomB0tkk2uycp9ROKHlrPy35MykqT1N2k4L83TUuvnmaGed93mIeQMYV7CpQ9LAASETNgcAPZLQdKRSxOyJBmySTOE0ZPyfAoOScXIXwDgEgpH5BBngqaTfiQLBetXzmj1lGpKrXCEqvmLnr6mEamrpp-UJWNNqpx3RCF1m_dtlO7KlLWY9W1pvZNn2CUN66qS3VJzgq1Dnh1qCPy9fK8nL3F88_X99l0HpuEiyZWNLWQJYoLUwDXaWFSVEIlTFArEqtyKFCgFcg0ZzpPrWZoM651XmR6AkUyItf73I2vf1oMjSxdMLheqwrrNsg8z2kqmOiE2V5ofB2Cx0JuvCuV_5UU5I6m7GnKHSoJmexpyp1vfDjQ6hLt0XXA1-0f93vsvtw69DKYjpNB6zyaRtra_XPhD6UnhVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77714969</pqid></control><display><type>article</type><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><source>ScienceDirect Journals</source><creator>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</creator><creatorcontrib>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</creatorcontrib><description>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients. Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid). Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/S0039-6060(05)80119-9</identifier><identifier>PMID: 7491528</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoma - genetics ; Adenoma - mortality ; Adenoma - surgery ; Adolescent ; Adrenal Cortex Neoplasms - genetics ; Adrenal Cortex Neoplasms - mortality ; Adrenal Cortex Neoplasms - surgery ; Adult ; Aged ; Aneuploidy ; Carcinoma - genetics ; Carcinoma - mortality ; Carcinoma - surgery ; Combined Modality Therapy ; DNA, Neoplasm - analysis ; Female ; Humans ; Male ; Middle Aged ; Mitotane - therapeutic use ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Survival Rate</subject><ispartof>Surgery, 1995-12, Vol.118 (6), p.1090-1098</ispartof><rights>1995 Mosby-Year Book, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</citedby><cites>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7491528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Berger, David H.</creatorcontrib><creatorcontrib>El-Naggar, Adel K.</creatorcontrib><creatorcontrib>Hickey, Robert C.</creatorcontrib><creatorcontrib>Vassilopoulou-Sellin, Rena</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Andrew Burgess, M.</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients. Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid). Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</description><subject>Adenoma - genetics</subject><subject>Adenoma - mortality</subject><subject>Adenoma - surgery</subject><subject>Adolescent</subject><subject>Adrenal Cortex Neoplasms - genetics</subject><subject>Adrenal Cortex Neoplasms - mortality</subject><subject>Adrenal Cortex Neoplasms - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aneuploidy</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - surgery</subject><subject>Combined Modality Therapy</subject><subject>DNA, Neoplasm - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitotane - therapeutic use</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Survival Rate</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkE1Lw0AQhhdRaq3-hEJOomB0tkk2uycp9ROKHlrPy35MykqT1N2k4L83TUuvnmaGed93mIeQMYV7CpQ9LAASETNgcAPZLQdKRSxOyJBmySTOE0ZPyfAoOScXIXwDgEgpH5BBngqaTfiQLBetXzmj1lGpKrXCEqvmLnr6mEamrpp-UJWNNqpx3RCF1m_dtlO7KlLWY9W1pvZNn2CUN66qS3VJzgq1Dnh1qCPy9fK8nL3F88_X99l0HpuEiyZWNLWQJYoLUwDXaWFSVEIlTFArEqtyKFCgFcg0ZzpPrWZoM651XmR6AkUyItf73I2vf1oMjSxdMLheqwrrNsg8z2kqmOiE2V5ofB2Cx0JuvCuV_5UU5I6m7GnKHSoJmexpyp1vfDjQ6hLt0XXA1-0f93vsvtw69DKYjpNB6zyaRtra_XPhD6UnhVg</recordid><startdate>19951201</startdate><enddate>19951201</enddate><creator>Lee, Jeffrey E.</creator><creator>Berger, David H.</creator><creator>El-Naggar, Adel K.</creator><creator>Hickey, Robert C.</creator><creator>Vassilopoulou-Sellin, Rena</creator><creator>Gagel, Robert F.</creator><creator>Andrew Burgess, M.</creator><creator>Evans, Douglas B.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951201</creationdate><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><author>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenoma - genetics</topic><topic>Adenoma - mortality</topic><topic>Adenoma - surgery</topic><topic>Adolescent</topic><topic>Adrenal Cortex Neoplasms - genetics</topic><topic>Adrenal Cortex Neoplasms - mortality</topic><topic>Adrenal Cortex Neoplasms - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aneuploidy</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - surgery</topic><topic>Combined Modality Therapy</topic><topic>DNA, Neoplasm - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitotane - therapeutic use</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Berger, David H.</creatorcontrib><creatorcontrib>El-Naggar, Adel K.</creatorcontrib><creatorcontrib>Hickey, Robert C.</creatorcontrib><creatorcontrib>Vassilopoulou-Sellin, Rena</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Andrew Burgess, M.</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jeffrey E.</au><au>Berger, David H.</au><au>El-Naggar, Adel K.</au><au>Hickey, Robert C.</au><au>Vassilopoulou-Sellin, Rena</au><au>Gagel, Robert F.</au><au>Andrew Burgess, M.</au><au>Evans, Douglas B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>1995-12-01</date><risdate>1995</risdate><volume>118</volume><issue>6</issue><spage>1090</spage><epage>1098</epage><pages>1090-1098</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><abstract>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients. Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid). Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>7491528</pmid><doi>10.1016/S0039-6060(05)80119-9</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0039-6060
ispartof Surgery, 1995-12, Vol.118 (6), p.1090-1098
issn 0039-6060
1532-7361
language eng
recordid cdi_proquest_miscellaneous_77714969
source ScienceDirect Journals
subjects Adenoma - genetics
Adenoma - mortality
Adenoma - surgery
Adolescent
Adrenal Cortex Neoplasms - genetics
Adrenal Cortex Neoplasms - mortality
Adrenal Cortex Neoplasms - surgery
Adult
Aged
Aneuploidy
Carcinoma - genetics
Carcinoma - mortality
Carcinoma - surgery
Combined Modality Therapy
DNA, Neoplasm - analysis
Female
Humans
Male
Middle Aged
Mitotane - therapeutic use
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Survival Rate
title Surgical management, DNA content, and patient survival in adrenal cortical carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T01%3A52%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20management,%20DNA%20content,%20and%20patient%20survival%20in%20adrenal%20cortical%20carcinoma&rft.jtitle=Surgery&rft.au=Lee,%20Jeffrey%20E.&rft.date=1995-12-01&rft.volume=118&rft.issue=6&rft.spage=1090&rft.epage=1098&rft.pages=1090-1098&rft.issn=0039-6060&rft.eissn=1532-7361&rft_id=info:doi/10.1016/S0039-6060(05)80119-9&rft_dat=%3Cproquest_cross%3E77714969%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77714969&rft_id=info:pmid/7491528&rfr_iscdi=true